Creating a new CAR-T therapy for blood cancers like AML and glioblastoma
Development of a novel pan-cancer CAR-T product against AML and Glioblastoma
This study is testing a new type of CAR-T cell therapy that aims to help people with tough cancers like acute myeloid leukemia and glioblastoma by training the immune cells to find and attack cancer cells that show a special marker called MR1.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kure. Ai, INC. NIH-funded |
| Lab location | 1 site (Shaker Heights, United States) |
| Project ID | NIH-11007100 on NIH RePORTER |
What this research studies
This research focuses on developing a novel CAR-T cell therapy targeting acute myeloid leukemia (AML) and glioblastoma, which are challenging cancers to treat. The approach involves using a unique target, the MR1 molecule, which is typically hidden inside cells but can appear on the surface of tumor cells when bound to specific cancer-related metabolites. By designing CAR-T cells that can recognize and attack these MR1-expressing tumor cells, the research aims to improve treatment outcomes for patients with these malignancies. The initial studies in mice have shown promising safety and efficacy results, paving the way for potential human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research would include patients diagnosed with acute myeloid leukemia or glioblastoma who have not responded to standard treatments.
Not a fit: Patients with early-stage cancers or those not diagnosed with AML or glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with AML and glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: While CAR-T therapies have shown success in treating certain blood cancers, this specific approach targeting MR1 in solid tumors and blood cancers is novel and has not been widely tested.
Where this research is happening
Shaker Heights, United States
- Kure. Ai, INC. — Shaker Heights, United States (Active)
Researchers
- Principal investigator: Soler, David — Kure. Ai, INC.
- Study coordinator: Soler, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.